Peter Murphy, MD
Pulmonary Disease · Omaha, NENPI 1174574586
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.8% of the total across 11 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Vertex at 27.8% of the total. That places this record below the midpoint for pulmonary disease clinicians in NE, where the typical reported total is $2,614.
Across 11 payments — averaging $34.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vertex$106
- Abiomed$98
- Gilead$96
- AbbVie$36
- Insmed, Inc.$16
- Fisher & Paykel Healthcare Inc$15
- plus $15 from 1 others
Across 10 payments — averaging $23,322 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vertex$233K
What the payments were for
- Food & beverage$36696%
- Education$164%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vertex | 4 | $106 |
| Abiomed | 1 | $98 |
| Gilead | 1 | $96 |
| AbbVie | 2 | $36 |
| Insmed, Inc. | 1 | $16 |
| Fisher & Paykel Healthcare Inc | 1 | $15 |
| Mylan Specialty L.p. | 1 | $15 |
How this compares
$382 in reported general payments places this provider in the 20th percentile of 81 pulmonary disease providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prolastin CAlpha-1-Proteinase Inhibitor | 12 | $114,271 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 78 | $56,500 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 67 | $34,938 |
| Spiriva HandihalerTiotropium Bromide | 34 | $30,062 |
| Incruse ElliptaUmeclidinium Bromide | 53 | $23,717 |
| Spiriva RespimatTiotropium Bromide | 23 | $22,174 |
| SymbicortBudesonide/Formoterol Fumarate | 49 | $16,881 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $5,287 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 22 | $4,655 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 11 | $2,449 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 93 | $2,431 |
| Roflumilast | 19 | $1,941 |
| Ventolin HfaAlbuterol Sulfate | 25 | $1,487 |
| Ipratropium Bromide | 29 | $781 |
| Montelukast Sodium | 48 | $449 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Omaha
- Stephen RennardOmaha$50K
- Douglas MooreOmaha$40K
- Adam WellsOmaha$26K
- Zachary DepewOmaha$26K
- Michael SanleyOmaha$17K
- Adam HighleyOmaha$15K
- Carolina LandeenOmaha$14K
- Patrick MeyersOmaha$12K
- John DickinsonOmaha$8K
- Palvannanathan GanesanOmaha$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.